Cargando…

A Review of Newly Diagnosed Glioblastoma

Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitant temozolomide chemotherapy followed by temozolomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Sandhu, Navjot, Knox, Susan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892469/ https://www.ncbi.nlm.nih.gov/pubmed/33614476 http://dx.doi.org/10.3389/fonc.2020.574012

Ejemplares similares

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

The War on Cancer: A Military Perspective
por: Oronsky, Bryan, et al.
Publicado: (2015)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Episensitization: Defying Time’s Arrow
por: Oronsky, Bryan T., et al.
Publicado: (2015)

Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
por: Oronsky, Bryan, et al.
Publicado: (2014)

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

Going viral: a review of replication-selective oncolytic adenoviruses
por: Larson, Christopher, et al.
Publicado: (2015)

A Review of Persistent Post-COVID Syndrome (PPCS)
por: Oronsky, Bryan, et al.
Publicado: (2021)

Rewriting the Epigenetic Code for Tumor Resensitization: A Review
por: Oronsky, Bryan, et al.
Publicado: (2014)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

The Implications of Hyponitroxia in Cancer
por: Oronsky, Bryan, et al.
Publicado: (2014)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm
por: Paulmurugan, Ramasamy, et al.
Publicado: (2013)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

No patient left behind: The promise of immune priming with epigenetic agents
por: Carter, Corey A., et al.
Publicado: (2017)

What Exactly Is Inflammation (and What Is It Not?) †
por: Oronsky, Bryan, et al.
Publicado: (2022)

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy
por: Oronsky, Bryan, et al.
Publicado: (2016)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

Could nucleocapsid be a next-generation COVID-19 vaccine candidate – author's reply
por: Oronsky, Bryan, et al.
Publicado: (2022)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
por: Oronsky, Bryan, et al.
Publicado: (2021)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer
por: Oronsky, Bryan, et al.
Publicado: (2018)

A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma
por: Zhao, Chao, et al.
Publicado: (2020)

Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
por: Vymazal, Josef, et al.
Publicado: (2023)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
por: Carter, Corey A., et al.
Publicado: (2016)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Profile EpicentRx, Inc
por: Oronsky, Bryan
Publicado: (2023)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87d77jng0va8ee2kkc2am615b9